A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 8, 2009, Pages 982-990

  Wu, Peggy A ^a   Kim, Youn H ^b   Lavori, Phillip W ^b   Hoppe, Richard T ^b   Stockerl Goldstein, Keith E ^c  

^a WASHINGTON UNIVERSITY   (United States)

^b STANFORD UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic stem cell transplant; Autologous stem cell transplant; Cutaneous T cell lymphoma; Mycosis fungoides; S zary Syndrome

Indexed keywords

BUSULFAN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN; MESNA; PREDNISONE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENDER; GRAFT VERSUS LYMPHOMA EFFECT; HUMAN; MALE; META ANALYSIS; MYCOSIS FUNGOIDES; SEZARY SYNDROME; SYSTEMATIC REVIEW; WHOLE BODY RADIATION;

ADULT; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; SEZARY SYNDROME; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 67649583532     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.04.017     Document Type: Article

References (39)

1. Girardi M., Heald P.W., and Wilson L.D. The pathogenesis of mycosis fungoides. N Engl J Med 350 (2004) 1978-1988
2. Willemze R., Jaffe E.S., Burg G., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 105 (2005) 3768-3785
3. Horwitz S.M., Olsen E.A., Duvic M., Porcu P., and Kim Y.H. Review of the treatment of mycosis fungoides and Sézary syndrome: a stage-based approach. J Natl Comp Cancer Netw 6 (2008) 436-442
4. Mycosis Fungoides/Sezary syndrome of the cutaneous T-cell lymphomas. NCCN Practice Guidelines in Oncology v12008. NCCN Practice Guidelines Oncol. 2008.
5. Kim Y.H., Liu H.L., Mraz-Gernhard S., Varghese A., and Hoppe R.T. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 139 (2003) 857-866
6. Herbert K., Spencer A., Grigg A., et al. Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma. Bone Marrow Transplant 34 (2004) 521-525
7. Jones R.J., Ambinder R.F., Piantadosi S., and Santos G.W. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77 (1991) 1383-1388
8. Duarte R., Schmitz N., Servitje O., and Sureda A. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant 41 (2008) 597-604
9. Bunn P., and Lamberg S. Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep 63 (1979) 725-728
10. Olsen E., Vonderheid E., Pimpinelli N., et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110 (2007) 1713-1722
11. Kaplan E., and Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 53 (1958) 457-481
12. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988) 1141-1154
13. Team RDC. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2005.
14. Guitart J., Wickless S.C., Oyama Y., et al. Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma. Arch Dermatol 138 (2002) 1359-1365
15. Olsen E.A., Kim Y.H., Kuzel T.M., et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25 (2007) 3109-3115
16. Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300 (1979) 1068-1073
17. Lee S., Cho B.S., Kim S.Y., et al. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease. Biol Blood Marrow Transplant 13 (2007) 1083-1094
18. Gassas A., Sung L., Saunders E., and Doyle J. Graft-versus-leukemia effect in hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia: significantly lower relapse rate in unrelated transplantation. Bone Marrow Transplant 40 (2007) 951-955
19. Maruyama D., Fukuda T., Kato R., et al. Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen. Biol Blood Marrow Transplant 13 (2007) 932-941
20. Lowsky R., Takahashi T., Liu Y.P., et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 353 (2005) 1321-1331
21. Soiffer R. Immune modulation and chronic graft-versus-host disease. Bone Marrow Transplant 42 (2008) S66-S69
22. Sprangers B., Van Wijmeersch B., Fevery S., Waer M., and Billiau A.D. Experimental and clinical approaches for optimization of the graft-versus-leukemia effect. Nat Clin Pract Oncol 4 (2007) 404-414
23. Liang Y., Liu C., Djeu J.Y., et al. Beta2 integrins separate graft-versus-host disease and graft-versus-leukemia effects. Blood 111 (2008) 954-962
24. Molina A., Zain J., Arber D.A., et al. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol 23 (2005) 6163-6171
25. Zecca M., Prete A., Rondelli R., et al. Chronic graft-versus-host disease in children: incidence, risk factors and impact on outcome. Blood 100 (2002) 1192-1200
26. Alyea E., Neuberg D., Mauch P., et al. Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 8 (2002) 139-144
27. Molina A., Nademanee A., Arber D.A., and Forman S.J. Remission of refractory Sezary syndrome after bone marrow transplantation from a matched unrelated donor. Biol Blood Marrow Transplant 5 (1999) 400-404
28. Burt R.K., Guitart J., Traynor A., et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect. Bone Marrow Transplant 25 (2000) 111-113
29. Masood N., Russell K.J., Olerud J.E., et al. Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation. J Am Acad Dermatol 47 (2002) 140-145
30. Soligo D., Ibatici A., Morandi P., et al. Treatment of advanced mycosis fungoides by allogeneic stem-cell transplantation with a nonmyeloablative regimen. Bone Marrow Transplant 31 (2003) 663-666
31. Koeppel M.-C., Stoppa A.-M., Resbeut M., et al. Mycosis fungoides and allogeneic bone marrow transplantation. Acta Derm Venereol 74 (1994) 331-332
32. Introcaso C.E., Leber B., Greene K., et al. Stem cell transplantation in advanced cutaneous T-cell lymphoma. J Am Acad Dermatol 58 (2008) 645-649
33. Ferra C., Servitje O., Petriz L., et al. Autologous haematopoietic progenitor transplantation in advanced mycosis fungoides. Br J Dermatol 140 (1999) 1188-1189
34. Sterling J.C., Marcus R., Burrows N.P., and Roberts S.O. Erythrodermic mycosis fungoides treated with total body irradiation and autologous bone marrow transplantation. Clin Exp Dermatol 20 (1995) 73-75
35. Olavarria E., Child F., Woolford A., et al. T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol 114 (2001) 624-631
36. Russell-Jones R., Child F., Olavarria E., et al. Autologous peripheral blood stem cell transplantation in tumor-stage mycosis fungoides: predictors of disease-free survival. Ann N Y Acad Sci 941 (2001) 147-154
37. Bigler R.D., Crilley P., Micaily B., et al. Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant 7 (1991) 133-137
38. Chen Y.C., Wang C.H., Huang S.C., et al. Autologous bone marrow transplantation after supralethal dose of total body irradiation in a case of mycosis fungoides. Taiwan Yi Xue Hui Za Zhi 85 (1986) 304-314
39. Ingen-Housz-Oro S., Bachelez H., Verola O., et al. High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma. Bone Marrow Transplant 33 (2004) 629-934